The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | The genomics of Waldenström’s macroglobulinemia and what this tells us about its curability
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the genomics of Waldenström’s macroglobulinemia (WM), and highlights the importance of using novel therapeutic agents to target CXCR4 and MYD88 mutations. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
